ATC Group: M05BA Bisphosphonates

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M05BA in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M05 Drugs for treatment of bone diseases
3 M05B Drugs affecting bone structure and mineralization
4 M05BA Bisphosphonates

Group M05BA contents

Code Title
M05BA01 Etidronic acid
M05BA02 Clodronic acid
M05BA03 Pamidronic acid
M05BA04 Alendronic acid
M05BA05 Tiludronic acid
M05BA06 Ibandronic acid
M05BA07 Risedronic acid
M05BA08 Zoledronic acid

Active ingredients in M05BA

Active Ingredient

Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.

Clodronic acid is a bisphosphonate, (formerly diphosphonates), a group of analogues of pyrophosphate, which have been shown, in vitro, to inhibit the formation and dissolution of calcium phosphate (hydroxyapatite). In vivo, they have been shown to inhibit bone resorption to a greater or lesser extent, depending on the compound, and clodronate is one of the most effective in this respect.

Etidronate acts primarily on bone. It can inhibit the formation, growth, and dissolution of hydroxyapatite crystals and their amorphous precursors by chemisorption to calcium phosphate surfaces.

Ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone. Their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral. Bisphosphonates act by inhibiting osteoclast activity, although the precise mechanism is still not clear. In vivo, ibandronic acid prevents experimentally-induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts.

The principal pharmacologic action of pamidronic acid is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronic acid adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone.

Risedronic acid is a pyridinyl bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. The bone turnover is reduced while the osteoblast activity and bone mineralisation is preserved.

Tiludronic acid is indicated for treatment of Paget’s disease of bone (osteitis deformans). In vitro studies indicate that tiludronate disodium acts primarily on bone through a mechanism that involves inhibition of osteoclastic activity with a probable reduction in the enzymatic and transport processes that lead to resorption of the mineralized matrix.

Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption.

Related product monographs

Document Type Information Source  
 ACTONEL Film-coated tablet MPI, EU: SmPC Marketing Authorisation Holder
 BINOSTO Effervescent tablet MPI, EU: SmPC Marketing Authorisation Holder
 BONDRONAT Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 BONDRONAT Film-coated tablets MPI, EU: SmPC European Medicines Agency (EU)
 BONEFOS Film-coated tablets MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 BONIVA Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 BONVIVA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 CLASTEON Capsule MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DENSATE Tablet MPI, Generic Marketing Authorisation Holder
 Fosamax MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 FOSAMAX Once Weekly Tablets MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 RISEDRONATE SODIUM 35 mg Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 RISONATE Film-coated tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 SKELID Tablet MPI, US: SPL/Old FDA, National Drug Code (US)
 ZERLINDA Solution for infusion MPI, EU: SmPC Health Products Regulatory Authority (IE)
 ZOBONE Concentrate for solution for infusion MPI, Generic Health Products Regulatory Authority (ZA)